Compare ACADIA Pharmaceuticals Inc. (ACAD) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs State Street SPDR S&P Homebuilders ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while State Street SPDR S&P Homebuilders ETF trades at $106.45. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | XHB | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $28.06 | $121.36 |
52-Week Low | $20.06 | $94.86 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
XHB (SPDR S&P Homebuilders ETF) trades at $111.29, down 1.13% amid mixed housing data. Technical indicators show a bullish bias with strong moving average support, while oscillators remain neutral. Recent news highlights declining new home sales but improving builder sentiment, creating a complex backdrop for the homebuilding sector.
The ETF faces headwinds from higher mortgage rates and construction costs, but potential exists if housing demand recovers. Key risks include interest rate sensitivity and economic uncertainty, while technical support near $108 provides a cushion for near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
